Breast Cancer Biomarker Guidelines Include Genomics
This article was originally published in The Gray Sheet
Executive Summary
The American Society of Clinical Oncology updated its seven-year old recommendations for the use of breast cancer biomarkers Oct. 22
You may also be interested in...
FDA Takes Second Stab At Multivariate Diagnostic Oversight Guidelines
FDA cautiously moved ahead with its controversial plan to actively regulate certain laboratory-developed tests with the release of a revised 1draft guidance document July 24
US FDA’s Anti-Misinformation Campaigns Look Safer After Supreme Court Oral Arguments
FDA’s efforts to tackle misinformation may face fewer legal obstacles moving forward, following oral arguments at the Supreme Court on a case that could have broad ramifications for how the government communicates public health information.
The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews
Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.